Abstract: A method of treating and/or lowering elevated cholesterol by administering a therapeutically effective amount of at least one 5HT1A receptor agonist to a subject in need thereof as either a short term or long term therapy. Also, a method of maintaining clinically acceptable cholesterol levels, or cholesterol levels below an elevated amount, by administering a therapeutically effective amount of at least one 5HT1A receptor agonist to a subject in need thereof as either a short term or long term therapy.

Abstract: A method of treatment of depression in a person also taking non-Steroidal anti-inflammatory drugs (NSAIDs) by administering gepirone as either a short term or long term therapy.

Abstract: The present invention relates to a method for alleviation, prevention, and treatment of attention deficit disorder, sexual dysfunction, and related conditions by administering certain bioactive metabolites of the known anti-depressant compound gepirone. In a preferred embodiment, the compound is 4,4,-dimethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione (3-OH gepirone).

Abstract: The present invention relates to a method for alleviation, prevention, and treatment of anxiety, depression, and sexual dysfunction by administering certain indolylalkyl derivatives of pyrimidinylpiperazine or metabolites thereof.

Abstract: The present invention relates to a method for alleviation, prevention, and treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, aggressive behavior, alcohol dependency, psychoses, and related conditions by administering adatanserin and/or metabolites of adatanserin. The present invention also relates to a method of weight loss by administering adatanserin and/or metabolites of adatanserin.

Abstract: The present invention provides a method for inducing sleep, by nasally administrating to a subject in need thereof a pharmaceutical composition containing zolpidem, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.

Abstract: The present invention relates to a method of treatment of sexual dysfunction e.g. female sexual disfunction by administering to a person in need of treatment an effective amount of gepirone as either a short-term or a long-term therapy.

Abstract: The present invention relates to high-dosage extended-release formulation of gepirone and methods of treating major depression by administering the same to a subject in need thereof. More specifically, the present invention relates to a high-dosage extended-release tablet form of gepirone. The present invention also relates to a method of treating depression in mammals by administering to a subject in need thereof an effective amount the high-dosage extended-release formulation of gepirone in accordance with the present invention.

Abstract: A pharmaceutical composition is provided, which includes: at least one active ingredient selected from the group including adatanserin, a compound having formula I, a compound having formula II, abaperidone, pharmaceutically acceptable salt thereof, prodrug thereof, and a mixture thereof; at least one high or medium viscosity hydroxypropylmethylcellulose (HPMC); at least one high or medium viscosity hydroxyethylcellulose (HEC); wherein the HPMC and HEC are present in a HPMC/HEC weight ratio ranging from 1/0.5 to 1/1.5; wherein adatanserin, abaperidone, and the compounds having formulas (I) and (II) are defined herein.

Abstract: One embodiment of the present invention provides a pharmaceutical composition for nasal administration, which includes zolpidem, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form. Another embodiment of the present invention provides a method for inducing sleep, which includes nasally administering to a subject in need thereof a pharmaceutical composition, which includes zolpidem, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.

Abstract: The present invention relates to a method for treatment of attention deficit disorder by administering certain 5-HT1A receptor agonists

Abstract: Bioactive gepirone metabolites, such as 3-OH gepirone (4,4,-dimethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione), and their pharmaceutically acceptable salts and hydrates, can be used to alleviate psychological disorders or the symptoms thereof. The use of these compounds provides advantages over other therapeutic azapirones as they possess superior bioavailability, faster onset of action, and more stable plasma levels when administered to a mammal.